Cutaneous neoplasms showing EWSR1 rearrangement

Advances in Anatomic Pathology

Volumn 20, Issue 2, 2013, Pages 75-85

  Boland, Jennifer M ^a   Folpe, Andrew L ^a  

^a MAYO CLINIC   (United States)

Author keywords

cutaneous; EWSR1; florescence in situ hybridization; sarcoma; Skin; soft tissue

Indexed keywords

CD56 ANTIGEN; CD68 ANTIGEN; CD99 ANTIGEN; CHROMOGRANIN; CYTOKERATIN; DESMIN; PROTEIN S 100; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR ERG;

BLUE NEVUS; CANCER GENETICS; CANCER MORPHOLOGY; CLEAR CELL SARCOMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EWING SARCOMA; FOLLICULAR DENDRITIC CELL SARCOMA; FUSION GENE; GENE REARRANGEMENT; GENETIC LINKAGE; GENETIC SCREENING; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOBLASTOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MERKEL CELL TUMOR; MIXED TUMOR; MOLECULAR WEIGHT; MYOEPITHELIOMA; NEOPLASM; NEUROECTODERM TUMOR; NOMENCLATURE; PERIVASCULAR EPITHELIOID CELL TUMOR; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SMALL CELL CARCINOMA;

CALMODULIN-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; GENE REARRANGEMENT; HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MYOEPITHELIOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; ONCOGENE PROTEINS, FUSION; RNA-BINDING PROTEINS; SARCOMA, CLEAR CELL; SARCOMA, EWING; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 84873925873     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31828625bf     Document Type: Review

References (122)

1. Blechingberg J, Holm IE, Nielsen AL. Characterization and expression analysis in the developing embryonic brain of the porcine FET family: FUS, EWS, and TAF15. Gene. 2012; 493: 27-35.
2. Bertolotti A, Lutz Y, Heard DJ, et al. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the prooncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 1996; 15: 5022-5031.
3. Aurias A, Rimbaut C, Buffe D, et al. Translocation of chromosome 22 in Ewing's sarcoma. C R Seances Acad Sci III. 1983; 296: 1105-1107.
4. Turc-Carel C, Philip I, Berger MP, et al. Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11; 22)(q24; q12). Cancer Genet Cytogenet. 1984; 12: 1-19.
5. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11; 22)(q24; q12). Cancer Genet Cytogenet. 1988; 32: 229-238.
6. Covinsky M, Gong S, Rajaram V, et al. EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma. Hum Pathol. 2005; 36: 74-81.
7. Thway K, Nicholson AG, Lawson K, et al. Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am J Surg Pathol. 2011; 35: 1722-1732.
8. Clark J, Benjamin H, Gill S, et al. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene. 1996; 12: 229-235.
9. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994; 54: 2837-2840.
10. Panagopoulos I, Hoglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene. 1996; 12: 489-494.
11. Speleman F, Delattre O, Peter M, et al. Malignant melanoma of the soft parts (clear-cell sarcoma): confirmation of EWS and ATF-1 gene fusion caused by a t(12; 22) translocation. Mod Pathol. 1997; 10: 496-499.
12. Rossi S, Szuhai K, Ijszenga M, et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007; 13: 7322-7328.
13. Antonescu CR, Zhang L, Chang NE, et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer. 2010; 49: 1114-1124.
14. Antonescu CR, Katabi N, Zhang L, et al. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clearcell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011; 50: 559-570.
15. Ewing J. Diffuse endothelioma of bone. Proc NY Soc Pathol. 1921; 21: 17-24.
16. Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer. 1975; 36: 240-251.
17. Fletcher CD, Unni KK, Mertens F. Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
18. Weiss SW, Goldblum Jr. Enzinger & Weiss's Soft Tissue Tumors. 5th ed. Mosby: Elsevier; 2008.
19. Collier AB III, Simpson L, Monteleone P. Cutaneous Ewing sarcoma: report of 2 cases and literature review of presentation, treatment, and outcome of 76 other reported cases. J Pediatric Hematol/Oncol. 2011; 33: 631-634.
20. Machado I, Llombart B, Calabuig-Farinas S, et al. Superficial Ewing's sarcoma family of tumors: a clinicopathological study with differential diagnoses. J Cutaneous Pathol. 2011; 38: 636-643.
21. Shingde MV, Buckland M, Busam KJ, et al. Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. J Clin Pathol. 2009; 62: 915-919.
22. Ehrig T, Billings SD, Fanburg-Smith JC. Superficial primitive neuroectodermal tumor/Ewing sarcoma (PN/ES): same tumor as deep PN/ES or new entity? Annals Diagn Pathol. 2007; 11: 153-159.
23. Hasegawa SL, Davison JM, Rutten A, et al. Primary cutaneous Ewing's sarcoma: immunophenotypic and molecular cytogenetic evaluation of five cases. Am J Surg Pathol. 1998; 22: 310-318.
24. Chow E, Merchant TE, Pappo A, et al. Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys. 2000; 46: 433-438.
25. Banerjee SS, Agbamu DA, Eyden BP, et al. Clinicopathological characteristics of peripheral primitive neuroectodermal tumour of skin and subcutaneous tissue. Histopathology. 1997; 31: 355-366.
26. Izquierdo MJ, Pastor MA, Carrasco L, et al. Cutaneous metastases from Ewing's sarcoma: report of two cases [case reports]. Clin Exp Dermatol. 2002; 27: 123-128.
27. Folpe AL, Goldblum JR, Rubin BP, et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005; 29: 1025-1033.
28. Nascimento AG, Unii KK, Pritchard DJ, et al. A clinicopathologic study of 20 cases of large-cell (atypical) Ewing's sarcoma of bone. Am J Surg Pathol. 1980; 4: 29-36.
29. Stevenson A, Chatten J, Bertoni F, et al. CD99 (p30/32MIC2) Neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker. Review of more than 600 tumors and the literature experience. Appl Immunohistochem. 1994; 2: 231-240.
30. Folpe AL, Schmidt RA, Chapman D, et al. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol. 1998; 22: 673-682.
31. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000; 24: 1657-1662.
32. Rossi S, Orvieto E, Furlanetto A, et al. Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody. Mod Pathol. 2004; 17: 547-552.
33. Wang WL, Patel NR, Caragea M, et al. Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. Mod Pathol. 2012; 6.
34. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol. 2011; 35: 432-441.
35. Gu M, Antonescu CR, Guiter G, et al. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol. 2000; 24: 410-416.
36. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992; 359: 162-165.
37. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21; 22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genet. 1994; 6: 146-151.
38. Jeon IS, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7; 22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995; 10: 1229-1234.
39. Urano F, Umezawa A, Hong W, et al. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun. 1996; 219: 608-612.
40. Peter M, Couturier J, Pacquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997; 14: 1159-1164.
41. Sorensen PH, Liu XF, Delattre O, et al. Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. Diagnostic Mol Pathol. 1993; 2: 147-157.
42. Downing JR, Head DR, Parham DM, et al. Detection of the (11; 22)(q24; q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol. 1993; 143: 1294-1300.
43. Taylor C, Patel K, Jones T, et al. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11; 22) using fluorescence in situ hybridisation. Brit J Cancer. 1993; 67: 128-133.
44. Shing DC, McMullan DJ, Roberts P, et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 2003; 63: 4568-4576.
45. Busam KJ, Jungbluth AA, Rekthman N, et al. Merkel cell polyomavirus expression in merkel cell carcinomas and its absence in combined tumors and pulmonary neuroendocrine carcinomas. Am J Surg Pathol. 2009; 33: 1378-1385.
46. Blessing K, Grant JJ, Sanders DS, et al. Small cell malignant melanoma: a variant of naevoid melanoma. Clinicopathological features and histological differential diagnosis. J Clin Pathol. 2000; 53: 591-595.
47. Enzinger FM. Angiomatoid malignant fibrous histiocytoma: a distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer. 1979; 44: 2147-2157.
48. Costa MJ, Weiss SW. Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome. Am J Surg Pathol. 1990; 14: 1126-1132.
49. Fanburg-Smith JC, Miettinen M. Angiomatoid "malignant" fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol. 1999; 30: 1336-1343.
50. Davies KA, Cope AP, Schofield JB, et al. A rare mediastinal tumour presenting with systemic effects due to IL-6 and tumour necrosis factor (TNF) production. Clin Exp Immunol. 1995; 99: 117-123.
51. Smith ME, Costa MJ, Weiss SW. Evaluation of CD68 and other histiocytic antigens in angiomatoid malignant fibrous histiocytoma [see comments]. Am J Surg Pathol. 1991; 15: 757-763.
52. Hasegawa T, Seki K, Ono K, et al. Angiomatoid (malignant) fibrous histiocytoma: a peculiar low-grade tumor showing immunophenotypic heterogeneity and ultrastructural variations. Pathol Int. 2000; 50: 731-738.
53. Fletcher CD. Angiomatoid "malignant fibrous histiocytoma": an immunohistochemical study indicative of myoid differentiation. Hum Pathol. 1991; 22: 563-568.
54. Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007; 46: 1051-1060.
55. Waters BL, Panagopoulos I, Allen EF. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by a chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet Cytogenet. 2000; 121: 109-116.
56. Wang WL, Mayordomo E, Zhang W, et al. Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol. 2009; 22: 1201-1209.
57. Hallor KH, Mertens F, Jin Y, et al. Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2005; 44: 97-102.
58. Panagopoulos I, Mertens F, Debiec-Rychter M, et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer. 2002; 99: 560-567.
59. Antonescu CR, Tschernyavsky SJ, Woodruff JM, et al. Molecular diagnosis of clear cell sarcoma: detection of EWSATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn. 2002; 4: 44-52.
60. Stockman DL, Miettinen M, Suster S, et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol. 2012; 36: 857-868.
61. Antonescu CR, Nafa K, Segal NH, et al. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma - association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006; 12: 5356-5362.
62. Flucke U, Mentzel T, Verdijk MA, et al. EWSR1-ATF1 chimeric transcript in a myoepithelial tumor of soft tissue: a case report. Hum Pathol. 2012; 43: 764-768.
63. Grogg KL, Lae ME, Kurtin PJ, et al. Clusterin expression distinguishes follicular dendritic cell tumors from other dendritic cell neoplasms: report of a novel follicular dendritic cell marker and clinicopathologic data on 12 additional follicular dendritic cell tumors and 6 additional interdigitating dendritic cell tumors. Am J Surg Pathol. 2004; 28: 988-998.
64. Laskowski J. Zarys onkologii. In: Kolodziejska H, ed. Pathology of Tumors. Warsaw: PZWL; 1995: 91-99.
65. Dabska M. Parachordoma: a new clinicopathologic entity. Cancer. 1977; 40: 1586-1592.
66. Folpe AL, Agoff SN, Willis J, et al. Parachordoma is immunohistochemically and cytogenetically distinct from axial chordoma and extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 1999; 23: 1059-1067.
67. Gimferrer JM, Baldo X, Montero CA, et al. Chest wall parachordoma. Eur J Cardiothorac Surg. 1999; 16: 573-575.
68. Hemalatha AL, Srinivasa MR, Parshwanath HA. Parachordoma of tibia - a case report. Ind J Pathol Microbiol. 2003; 46: 454-455.
69. Hirokawa M, Manabe T, Sugihara K. Parachordoma of the buttock: an immunohistochemical case study and review. Jpn J Clin Oncol. 1994; 24: 336-339.
70. Karabela-Bouropoulou V, Skourtas C, Liapi-Avgeri G, et al. Parachordoma. A case report of a very rare soft tissue tumor. Pathol Res Pract. 1996; 192: 972-978; discussion 9-81.
71. Ishida T, Oda H, Oka T, et al. Parachordoma: an ultrastructural and immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1993; 422: 239-245.
72. Imlay SP, Argenyi ZB, Stone MS, et al. Cutaneous parachordoma. A light microscopic and immunohistochemical report of two cases and review of the literature. J Cutan Pathol. 1998; 25: 279-284.
73. Koh JS, Chung JH, Lee SY, et al. Parachordoma of the tibia: report of a rare case. Pathol Res Pract. 2000; 196: 269-273.
74. Sangueza OP, White CR Jr. Parachordoma. Am J Dermatopathol. 1994; 16: 185-188.
75. Kilpatrick SE, Hitchcock MG, Kraus MD, et al. Mixed tumors and myoepitheliomas of soft tissue: a clinicopathologic study of 19 cases with a unifying concept [see comments]. Am J Surg Pathol. 1997; 21: 13-22.
76. Hornick JL, Fletcher CD. Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2003; 27: 1183-1196.
77. Gleason BC, Fletcher CD. Myoepithelial carcinoma of soft tissue in children: an aggressive neoplasm analyzed in a series of 29 cases. Am J Surg Pathol. 2007; 31: 1813-1824.
78. Michal M, Miettinen M. Myoepitheliomas of the skin and soft tissues. Report of 12 cases. Virchows Arch. 1999; 434: 393-400.
79. Flucke U, Palmedo G, Blankenhorn N, et al. EWSR1 gene rearrangement occurs in a subset of cutaneous myoepithelial tumors: a study of 18 cases. Mod Pathol. 2011; 24: 1444-1450.
80. Hornick JL, Fletcher CD. Cutaneous myoepithelioma: a clinicopathologic and immunohistochemical study of 14 cases. Hum Pathol. 2004; 35: 14-24.
81. Kutzner H, Mentzel T, Kaddu S, et al. Cutaneous myoepithelioma: an under-recognized cutaneous neoplasm composed of myoepithelial cells. Am J Surg Pathol. 2001; 25: 348-355.
82. Kuhnen C, Herter P, Kasprzynski A, et al. Myoepithelioma of soft tissue - case report with clinicopathologic, ultrastructural, and cytogenetic findings. Pathologe. 2005; 26: 331-337.
83. Kilpatrick SE, Hitchcock MG, Kraus MD, et al. Mixed tumors and myoepitheliomas of soft tissue: a clinicopathologic study of 19 cases with a unifying concept. Am J Surg Pathol. 1997; 21: 13-22.
84. Miettinen M, Karaharju E, Jarvinen H. Chordoma with a massive spindle-cell sarcomatous transformation. A light- and electron-microscopic and immunohistological study. Am J Surg Pathol. 1987; 11: 563-570.
85. Abe S, Imamura T, Harasawa A, et al. Parachordoma with multiple metastases. J Comput Assist Tomogr. 2003; 27: 634-638.
86. Mentzel T. Myoepithelial neoplasms of skin and soft tissues. Pathologe. 2005; 26: 322-330.
87. Tirabosco R, Mangham DC, Rosenberg AE, et al. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/ myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 2008; 32: 572-580.
88. Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011; 35: e47-e63.
89. Brandal P, Panagopoulos I, Bjerkehagen B, et al. Detection of a t(1; 22)(q23; q12) translocation leading to an EWSR1-PBX1 fusion gene in a myoepithelioma. Genes Chromosomes Cancer. 2008; 47: 558-564.
90. Brandal P, Panagopoulos I, Bjerkehagen B, et al. t(19; 22)(q13; q12) Translocation leading to the novel fusion gene EWSR1-ZNF444 in soft tissue myoepithelial carcinoma. Genes Chromosomes Cancer. 2009; 48: 1051-1056.
91. Flucke U, Tops BB, Verdijk MA, et al. NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma. Virchows Arch. 2012; 460: 621-628.
92. Bahrami A, Dalton JD, Krane JF, et al. A subset of cutaneous and soft tissue mixed tumors are genetically linked to their salivary gland counterpart. Genes Chromosomes Cancer. 2012; 51: 140-148.
93. LeBoit PE, Burg G, Weedon D, et al. Pathology & Genetics of Skin Tumors. Lyon: IARC Press; 2006.
94. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006; 209: 157-165.
95. Graham RP, Dry S, Li X, et al. Ossifying fibromyxoid tumor of soft parts: a clinicopathologic, proteomic, and genomic study. Am J Surg Pathol. 2011; 35: 1615-1625.
96. Gebre-Medhin S, Nord KH, Moller E, et al. Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors. Am J Pathol. 2012; 181: 1069-1077.
97. Enzinger FM. Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. Cancer. 1965; 18: 1163-1174.
98. Hoffman GJ, Carter D. Clear cell sarcoma of tendons and aponeuroses with melanin. Arch Pathol. 1973; 95: 22-25.
99. Chung EB, Enzinger FM. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am J Surg Pathol. 1983; 7: 405-413.
100. Deenik W, Mooi WJ, Rutgers EJ, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 30 cases. Cancer. 1999; 86: 969-975.
101. Hantschke M, Mentzel T, Rutten A, et al. Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma. Am J Surg Pathol. 2010; 34: 216-222.
102. Hisaoka M, Ishida T, Kuo TT, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol. 2008; 32: 452-460.
103. Coindre JM, Hostein I, Terrier P, et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group. Cancer. 2006; 107: 1055-1064.
104. van Akkooi AC, Verhoef C, van Geel AN, et al. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol. 2006; 32: 996-999.
105. Kindblom LG, Lodding P, Angervall L. Clear-cell sarcoma of tendons and aponeuroses. An immunohistochemical and electron microscopic analysis indicating neural crest origin. Virchows Arch A Pathol Anat Histopathol. 1983; 401: 109-128.
106. Mechtersheimer G, Tilgen W, Klar E, et al. Clear cell sarcoma of tendons and aponeuroses: case presentation with special reference to immunohistochemical findings. Hum Pathol. 1989; 20: 914-917.
107. Swanson PE, Wick MR. Clear cell sarcoma. An immunohistochemical analysis of six cases and comparison with other epithelioid neoplasms of soft tissue. Arch Pathol Lab Med. 1989; 113: 55-60.
108. Reeves BR, Fletcher CD, Gusterson BA. Translocation t(12; 22)(q13; q13) is a nonrandom rearrangement in clear cell sarcoma. Cancer Genet Cytogenet. 1992; 64: 101-103.
109. Patel RM, Downs-Kelly E, Weiss SW, et al. Dual-color, break-apart fluorescence in situ hybridization for EWS gene rearrangement distinguishes clear cell sarcoma of soft tissue from malignant melanoma. Mod Pathol. 2005; 18: 1585-1590.
110. Langezaal SM, Graadt van Roggen JF, Cleton-Jansen AM, et al. Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer. 2001; 84: 535-538.
111. Hocar O, Le Cesne A, Berissi S, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract. 2012. [Epub ahead of print, doi: 10.1155/2012/984096].
112. Negri T, Brich S, Conca E, et al. Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. Genes Chromosomes Cancer. 2012; 51: 111-126.
113. Panagopoulos I, Mertens F, Isaksson M, et al. Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). Cancer Genet Cytogenet. 2005; 156: 74-76.
114. Yang L, Chen Y, Cui T, et al. Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol. 2012; 43: 1463-1470.
115. Gammon B, Gerami P. Fluorescence in situ hybridization for ambiguous melanocytic tumors. Histol Histopathol. 2012; 27: 1539-1542.
116. Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol. 2012; 36: 808-817.
117. Kerl K, Palmedo G, Wiesner T, et al. A proposal for improving multicolor FISH sensitivity in the diagnosis of malignant melanoma using new combined criteria. Am J Dermatopathol. 2012; 34: 580-585.
118. Folpe AL, Kwiatkowski DJ. Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol. 2010; 41: 1-15.
119. Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005; 29: 1558-1575.
120. Folpe AL. Association of the t(12; 22)(q13; q12) EWS/ATF1 rearrangement with polyphenotypic round cell sarcoma of bone: a case report. Am J Surg Pathol. 2006; 30: 1057-1058, author reply 8-9.
121. Doyle LA, Wang WL, Dal Cin P, et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am J Surg Pathol. 2012; 36: 1444-1451.
122. Barr FG, Zhang PJ. The impact of genetics on sarcoma diagnosis: an evolving science. Clin Cancer Res. 2006; 12: 5256-5257.